Because only the impact of SHBG on the therapeutic effect and recurrence risk of breast cancer during and after endocrine therapy needs to be analyzed, this is beneficial for clarifying the correlation between SHBG changes and endocrine therapy resistance of ER-positive breast cancer (Figure 3). The gene discussed is SHBG; the disease is breast carcinoma.